Chronic Kidney Disease Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
In March 2025, Shandong Suncadia Medicine Co., Ltd. conducted a phase II Clinical Study of Efficacy and Safety of HRS-1780 ...
Medscape5d
New Therapy Update: INSPRA (eplerenone tablets)
Aldosterone is known to bind to these receptors in the kidney and cardiovascular system, increasing blood pressure through increasing sodium reabsorption and probably other mechanisms. The drug is ...
Nature5mon
Physiological Partial Aldosterone Resistance in Human Newborns
The human kidney displays a tubular immaturity at ... Sodium reabsorption is mainly controlled by aldosterone, a steroid hormone synthesized in the zona glomerulosa of the adrenal gland, secondary ...
Yahoo Finance21d
Mineralys Therapeutics Announces Proposed Public Offering of Common Stock
chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that it has commenced an underwritten public offering of $250.0 ...
Medscape24d
Balancing Diuretic Therapy in Heart Failure: Loop Diuretics, Thiazides, and Aldosterone Antagonists
The activated neurohormones angiotensin II, aldosterone, and norepinephrine ... and therefore better diuretic delivery to the kidneys. Hence, supine positioning can increase the diuretic response ...
Mineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock
BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Stifel and Wells Fargo Securities acted as joint book-running managers for the offering. LifeSci Capital acted as lead manager and H.C.